Table II.
Front-line treatments by age group.
| Characteristic, n (%) | ≤60 years (n = 1255) | 61–80 years (n = 1186) | >80 years (n = 209) | P value (Pearson χ2) |
|---|---|---|---|---|
| Watchful waiting | 241 (19·2) | 265 (22·3) | 51 (24·4) | < 0·001 |
|
| ||||
| R-mono | 121 (9·6) | 174 (14·7) | 60 (28·7) | |
|
| ||||
| R-chemo | 651 (51·9) | 566 (47·7) | 67 (32·1) | |
|
| ||||
| Other treatments | 242 (19·3) | 181 (15·3) | 31 (14·8) | |
| Chemo* | 31 (12·8) | 31 (17·1) | 9 (29·0) | |
| Radiotherapy* | 54 (22·3) | 61 (33·7) | 10 (32·3) | |
| Combined modality: radiotherapy* | 41 (16·9) | 31 (17·1) | 6 (19·4) | |
| Investigational therapy* | 104 (43·0) | 49 (27·1) | 5 (16·1) | |
| Other* | 12 (5·0) | 9 (5·0) | 1 (3·2) | |
|
| ||||
| Anthracycline use among Chemo/R-chemo therapy† | 456 (68·3) | 332 (58·1) | 21 (28·4) | < 0·001 |
|
| ||||
| R-maintenance use‡ | ||||
| After R-mono/R-chemo induction | 274 (46·3) | 230 (44·3) | 37 (48·7) | 0·688 |
| After R-mono induction | 51 (60·7) | 58 (48·3) | 14 (37·8) | 0·048 |
| After R-chemo induction | 223 (43·9) | 172 (43·1) | 23 (59·0) | 0·160 |
Chemo, chemotherapy; R-chemo, rituximab plus chemotherapy; R-maintenance, rituximab maintenance; R-mono, rituximab monotherapy.
*
Percentages are calculated among patients receiving Other Treatments.
†
Percentages are calculated among patients receiving front-line Chemo/R-chemo therapy.
‡
Patients who have completed the induction treatment, with a complete response, partial response, or stable disease who have not progressed or started second-line treatment 7 months after the end of induction are included in this analysis.